sotrovimab
AssetAlso called VIR-7831, sotrovimab, GSK-4182136, Xevudy
Monoclonal antibody engineered for immune engagement.
- Stage
- Phase 3, no development reported
- Modality
- Antibody
- Target
- S
- 1
- Indication
- 2
- Trials
- 2
- Developers
No development reported since July 2023. Last activity: Trial NCT05305651 completed. clinicaltrials.gov
Indications
1COVID-19
Phase 3, Completed, NCT05305651, clinicaltrials.gov, Oct 27, 2026
In the full profile
- Target and mechanism1
- Owner and partners6
- Trials2
- Evidence for its targets1
- Competitors11
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.